Logo image of CRVO

CERVOMED INC (CRVO) Stock Overview

NASDAQ:CRVO - US15713L1098 - Common Stock

10 USD
-0.28 (-2.72%)
Last: 9/9/2025, 8:00:00 PM

CRVO Key Statistics, Chart & Performance

Key Statistics
52 Week High19.5
52 Week Low1.8
Market Cap92.50M
Shares9.25M
Float6.34M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.61
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO11-09 2016-11-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CRVO short term performance overview.The bars show the price performance of CRVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40 50

CRVO long term performance overview.The bars show the price performance of CRVO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of CRVO is 10 USD. In the past month the price increased by 5.26%. In the past year, price decreased by -42.89%.

CERVOMED INC / CRVO Daily stock chart

CRVO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.72B
AMGN AMGEN INC 12.84 150.72B
GILD GILEAD SCIENCES INC 14.96 143.64B
VRTX VERTEX PHARMACEUTICALS INC 23.4 101.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.20B
REGN REGENERON PHARMACEUTICALS 12.19 58.99B
ARGX ARGENX SE - ADR 82.74 46.94B
ONC BEONE MEDICINES LTD-ADR 6.15 41.74B
INSM INSMED INC N/A 31.11B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 24.21B
BIIB BIOGEN INC 8.97 21.05B

About CRVO

Company Profile

CRVO logo image CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Company Info

CERVOMED INC

20 Park Plaza, Suite 424

Boston MASSACHUSETTS US

Employees: 15

CRVO Company Website

Phone: 16177444400

CERVOMED INC / CRVO FAQ

What is the stock price of CERVOMED INC today?

The current stock price of CRVO is 10 USD. The price decreased by -2.72% in the last trading session.


What is the ticker symbol for CERVOMED INC stock?

The exchange symbol of CERVOMED INC is CRVO and it is listed on the Nasdaq exchange.


On which exchange is CRVO stock listed?

CRVO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CERVOMED INC stock?

12 analysts have analysed CRVO and the average price target is 20.91 USD. This implies a price increase of 109.1% is expected in the next year compared to the current price of 10. Check the CERVOMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CERVOMED INC worth?

CERVOMED INC (CRVO) has a market capitalization of 92.50M USD. This makes CRVO a Micro Cap stock.


How many employees does CERVOMED INC have?

CERVOMED INC (CRVO) currently has 15 employees.


What are the support and resistance levels for CERVOMED INC (CRVO) stock?

CERVOMED INC (CRVO) has a support level at 9.12 and a resistance level at 10.52. Check the full technical report for a detailed analysis of CRVO support and resistance levels.


Is CERVOMED INC (CRVO) expected to grow?

The Revenue of CERVOMED INC (CRVO) is expected to decline by -28.8% in the next year. Check the estimates tab for more information on the CRVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CERVOMED INC (CRVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CERVOMED INC (CRVO) stock pay dividends?

CRVO does not pay a dividend.


When does CERVOMED INC (CRVO) report earnings?

CERVOMED INC (CRVO) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of CERVOMED INC (CRVO)?

CERVOMED INC (CRVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.61).


What is the Short Interest ratio of CERVOMED INC (CRVO) stock?

The outstanding short interest for CERVOMED INC (CRVO) is 5.23% of its float. Check the ownership tab for more information on the CRVO short interest.


CRVO Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CRVO. When comparing the yearly performance of all stocks, CRVO is a bad performer in the overall market: 71.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CRVO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CRVO. CRVO has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRVO Financial Highlights

Over the last trailing twelve months CRVO reported a non-GAAP Earnings per Share(EPS) of -2.61. The EPS decreased by -48.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -59.38%
ROE -67.62%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-159.26%
Sales Q2Q%-46.56%
EPS 1Y (TTM)-48.3%
Revenue 1Y (TTM)-19.47%

CRVO Forecast & Estimates

12 analysts have analysed CRVO and the average price target is 20.91 USD. This implies a price increase of 109.1% is expected in the next year compared to the current price of 10.

For the next year, analysts expect an EPS growth of -11.85% and a revenue growth -28.8% for CRVO


Analysts
Analysts81.67
Price Target20.91 (109.1%)
EPS Next Y-11.85%
Revenue Next Year-28.8%

CRVO Ownership

Ownership
Inst Owners26.29%
Ins Owners25.03%
Short Float %5.23%
Short Ratio0.79